Study S000430

Semaglutide as Treatment of Overweight and Obese Individuals to Reduce Atrial Fibrillation Burden

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05209165
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: QUADRUPLE
Status: SUSPENDED
Enrollment: 132
Start: 2023-05
Primary completion: 2027-05
Lead sponsor: San Francisco Veterans Affairs Medical Center
Conditions: Atrial Fibrillation; Obesity; Overweight
Interventions: DRUG:Semaglutide; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Atrial fibrillation burden [52 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.